Emergent BioSolutions (EBS) Total Debt Growth (3y) (2013 - 2026)
Emergent BioSolutions (EBS) Total Debt Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | -2.21% |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -7.03% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.29% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 63.29% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 1,183.78% |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -7.76% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -14.15% |
| 10 | Emergent BioSolutions | 389.77 Mn | 228.27 Mn | 84.10 Mn | 8.61% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.61% |
| Dec 31, 2025 | 8.45% |
| Sep 30, 2025 | -12.43% |
| Jun 30, 2025 | -5.62% |
| Mar 31, 2025 | -7.50% |
| Dec 31, 2024 | -7.90% |
| Sep 30, 2024 | -6.52% |
| Jun 30, 2024 | 0.01% |
| Mar 31, 2024 | 2.96% |
| Dec 31, 2023 | -19.03% |
| Sep 30, 2023 | -19.16% |
| Jun 30, 2023 | 5.23% |
| Mar 31, 2023 | -16.28% |
| Dec 31, 2022 | -18.41% |
| Sep 30, 2022 | 5.02% |
| Jun 30, 2022 | -2.01% |
| Mar 31, 2022 | 1.89% |
| Dec 31, 2021 | 2.45% |
| Sep 30, 2021 | 299.12% |
| Jun 30, 2021 | 300.12% |